Market Place
Sourcing Support
Pfizer snaps up rights to RSV therapy left behind in ReViral
20 Dec 2022 //
FIERCEBIOTECH
Pfizer Completes Acquisition Of ReViral
10 Jun 2022 //
CPI
Pfizer buys a private biotech and its RSV drug research
08 Apr 2022 //
BIOPHARMADIVE
ReViral Appoints Brett Haumann as Chief Medical Officer
17 Jan 2022 //
BUSINESSWIRE
ReViral to continue Phase II paediatric trial of sisunatovir for RSV
17 Jun 2021 //
CLINICAL TRAILS ARENA
ReViral Announces Positive Recommendation by the DSMC for Sisunatovir
16 Jun 2021 //
BUSINESSWIRE
ReViral and LianBio Announce Exclusive Collaboration and License Agreement
02 Mar 2021 //
BUSINESSWIRE
ReViral Raises $44 Million in Series C Financing
25 Aug 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.